Tag: John Bonfiglio

TapImmune Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients

TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for...

Top Biotech Trends for 2017

No doubt about it—2016 was a tumultuous year for biotech. But that doesn’t mean you should be afraid of this...

Investing in Immuno-Oncology: A Q&A with TapImmune's John Bonfiglio

TapImmune CEO, Dr. John Bonfiglio, on the immuno-oncology market, plus what you should keep in mind when comparing immuno-oncology companies.